{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T15:55:54Z","timestamp":1765554954968,"version":"build-2065373602"},"reference-count":141,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.cld.2019.06.004","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:50:49Z","timestamp":1565139049000},"page":"713-736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Pharmacologic Management of Portal Hypertension"],"prefix":"10.1016","volume":"23","author":[{"given":"Chalermrat","family":"Bunchorntavakul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Rajender","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cld.2013.12.003","article-title":"Pharmacologic management of portal hypertension","volume":"18","author":"Berzigotti","year":"2014","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2019.06.004_bib3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12072-017-9833-y","article-title":"Pharmacologic prevention of variceal bleeding and rebleeding","volume":"12","author":"Baiges","year":"2018","journal-title":"Hepatol Int"},{"issue":"9361","key":"10.1016\/j.cld.2019.06.004_bib4","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0140-6736(03)12778-X","article-title":"Prevention of variceal rebleeding","volume":"361","author":"Bosch","year":"2003","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.cld.2019.06.004_bib5","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2019.06.004_bib6","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2019.06.004_bib7","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/hep.23689","article-title":"Carvedilol for portal hypertension in patients with cirrhosis","volume":"51","author":"Bosch","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2019.06.004_bib8","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jhep.2007.02.006","article-title":"Vascular endothelial dysfunction in cirrhosis","volume":"46","author":"Iwakiri","year":"2007","journal-title":"J\u00a0Hepatol"},{"issue":"33","key":"10.1016\/j.cld.2019.06.004_bib9","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.3748\/wjg.v24.i33.3738","article-title":"Antiangiogenic therapy for portal hypertension in liver cirrhosis: current progress and perspectives","volume":"24","author":"Garbuzenko","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"issue":"21","key":"10.1016\/j.cld.2019.06.004_bib11","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMoa044456","article-title":"Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis","volume":"353","author":"Groszmann","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2019.06.004_bib12","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2006.09.013","article-title":"Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review","volume":"131","author":"D'Amico","year":"2006","journal-title":"Gastroenterology"},{"issue":"3 Suppl","key":"10.1016\/j.cld.2019.06.004_bib13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1136\/gut.35.3_Suppl.S1","article-title":"Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects","volume":"35","author":"Harris","year":"1994","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cld.2019.06.004_bib14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2036.2003.01657.x","article-title":"Pharmacological rationale for the use of somatostatin and analogues in portal hypertension","volume":"18","author":"Reynaert","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.cld.2019.06.004_bib15","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1053\/jhep.2002.33469","article-title":"Somatostatin and analogues in portal hypertension","volume":"35","author":"Abraldes","year":"2002","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib16","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/0016-5085(81)90014-7","article-title":"Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin","volume":"80","author":"Bosch","year":"1981","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/gast.2001.25536","article-title":"Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding","volume":"121","author":"Villanueva","year":"2001","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib18","first-page":"106","article-title":"Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation","volume":"22","author":"Cirera","year":"1995","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2019.06.004_bib19","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0168-8278(01)00206-9","article-title":"Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding","volume":"35","author":"Moitinho","year":"2001","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0168-8278(94)80142-8","article-title":"Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension","volume":"21","author":"Albillos","year":"1994","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2019.06.004_bib21","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1053\/gast.2002.32395","article-title":"Effects of long-term propranolol and octreotide on postprandial hemodynamics in cirrhosis: a randomized, controlled trial","volume":"122","author":"Vorobioff","year":"2002","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.cld.2019.06.004_bib22","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/j.1572-0241.2007.01390.x","article-title":"Octreotide enhances portal pressure reduction induced by propranolol in cirrhosis: a randomized, controlled trial","volume":"102","author":"Vorobioff","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib23","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib24","article-title":"Somatostatin analogues for acute bleeding oesophageal varices","author":"Gotzsche","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1053\/jhep.2002.31354","article-title":"Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis","volume":"35","author":"Banares","year":"2002","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2019.06.004_bib26","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1053\/gast.2001.22451","article-title":"Octreotide for acute esophageal variceal bleeding: a meta-analysis","volume":"120","author":"Corley","year":"2001","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1034\/j.1600-0676.2000.020001051.x","article-title":"Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients","volume":"20","author":"Moller","year":"2000","journal-title":"Liver"},{"issue":"11","key":"10.1016\/j.cld.2019.06.004_bib28","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1111\/j.1440-1746.2009.05873.x","article-title":"Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis","volume":"24","author":"Narahara","year":"2009","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib29","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1572-0241.2005.41381.x","article-title":"Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison","volume":"100","author":"Baik","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib30","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1572-0241.2004.40665.x","article-title":"Hemodynamic effects of terlipressin and high somatostatin dose during acute variceal bleeding in nonresponders to the usual somatostatin dose","volume":"100","author":"Villanueva","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"48","key":"10.1016\/j.cld.2019.06.004_bib31","doi-asserted-by":"crossref","first-page":"e13437","DOI":"10.1097\/MD.0000000000013437","article-title":"Terlipressin for the treatment of acute variceal bleeding: a systematic review and meta-analysis of randomized controlled trials","volume":"97","author":"Zhou","year":"2018","journal-title":"Medicine"},{"issue":"11","key":"10.1016\/j.cld.2019.06.004_bib32","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/j.1365-2036.2012.05088.x","article-title":"Meta-analysis: vasoactive medications for\u00a0the management of acute variceal bleeds","volume":"35","author":"Wells","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2036.2003.01356.x","article-title":"Systematic review: terlipressin in acute oesophageal variceal haemorrhage","volume":"17","author":"Ioannou","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.cld.2019.06.004_bib34","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3109\/00365529009095539","article-title":"Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled trial","volume":"25","author":"Soderlund","year":"1990","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2019.06.004_bib35","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1159\/000375346","article-title":"The treatment of hepatorenal syndrome","volume":"33","author":"Cavallin","year":"2015","journal-title":"Dig Dis"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib36","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.28396","article-title":"Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study","volume":"63","author":"Cavallin","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2019.06.004_bib37","article-title":"Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome","author":"Allegretti","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S2468-1253(16)30157-1","article-title":"Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis","volume":"2","author":"Facciorusso","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2019.06.004_bib39","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib40","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hep.21094","article-title":"The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond","volume":"43","author":"Moreau","year":"2006","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2019.06.004_bib41","article-title":"Terlipressin versus other vasoactive drugs for hepatorenal syndrome","author":"Israelsen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.cld.2019.06.004_bib42","doi-asserted-by":"crossref","first-page":"e107466","DOI":"10.1371\/journal.pone.0107466","article-title":"Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis","volume":"9","author":"Nassar Junior","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial","volume":"62","author":"Cavallin","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2019.06.004_bib44","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","article-title":"Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis","volume":"58","author":"Reiberger","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2019.06.004_bib45","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/liv.12782","article-title":"Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials","volume":"35","author":"Thiele","year":"2015","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.cld.2019.06.004_bib46","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s12325-013-0044-1","article-title":"Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective beta-blockers","volume":"30","author":"Madsen","year":"2013","journal-title":"Adv Ther"},{"issue":"8187","key":"10.1016\/j.cld.2019.06.004_bib47","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0140-6736(80)90063-X","article-title":"Propranolol--a medical treatment for portal hypertension?","volume":"2","author":"Lebrec","year":"1980","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.cld.2019.06.004_bib48","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1056\/NEJM198112033052302","article-title":"Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study","volume":"305","author":"Lebrec","year":"1981","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib49","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/hep.23852","article-title":"Beta-blockers in cirrhosis: friend and foe?","volume":"52","author":"Wong","year":"2010","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2019.06.004_bib50","article-title":"Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults","author":"Gluud","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib51","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/ajg.2011.456","article-title":"Development of ascites in compensated cirrhosis with severe portal hypertension treated with beta-blockers","volume":"107","author":"Hernandez-Gea","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"10181","key":"10.1016\/j.cld.2019.06.004_bib52","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib53","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hep.28264","article-title":"Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension","volume":"63","author":"Villanueva","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib54","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.23775","article-title":"Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites","volume":"52","author":"Serste","year":"2010","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2019.06.004_bib55","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.cgh.2016.01.012","article-title":"Nonselective beta-blockers and survival in patients with cirrhosis and ascites: a systematic review and meta-analysis","volume":"14","author":"Chirapongsathorn","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib56","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.510300124","article-title":"Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis","volume":"30","author":"Banares","year":"1999","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2019.06.004_bib57","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/apt.12634","article-title":"Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis","volume":"39","author":"Sinagra","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.cld.2019.06.004_bib58","doi-asserted-by":"crossref","first-page":"e010902","DOI":"10.1136\/bmjopen-2015-010902","article-title":"Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis","volume":"6","author":"Li","year":"2016","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.cld.2019.06.004_bib59","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2013.11.019","article-title":"Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial","volume":"60","author":"Shah","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib60","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/hep.23045","article-title":"Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed","volume":"50","author":"Tripathi","year":"2009","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2019.06.004_bib61","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1440-1746.2012.07244.x","article-title":"Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding","volume":"27","author":"Lo","year":"2012","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2019.06.004_bib62","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jhep.2014.06.015","article-title":"Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding","volume":"61","author":"Stanley","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib63","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0168-8278(90)90112-5","article-title":"Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension","volume":"11","author":"Garcia-Pagan","year":"1990","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2019.06.004_bib64","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/0016-5085(89)91630-2","article-title":"Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function","volume":"96","author":"Navasa","year":"1989","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2019.06.004_bib65","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1365-2036.2010.04418.x","article-title":"Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices","volume":"32","author":"Gluud","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.cld.2019.06.004_bib66","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/hep.1840360611","article-title":"\"A La Carte\" treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding","volume":"36","author":"Bureau","year":"2002","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2019.06.004_bib67","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/0016-5085(95)90586-3","article-title":"Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function","volume":"109","author":"Albillos","year":"1995","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib68","first-page":"611","article-title":"Hemodynamic effects of alpha-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension","volume":"20","author":"Albillos","year":"1994","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2019.06.004_bib69","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0016-5085(00)70368-4","article-title":"Angiotensin II induces contraction and proliferation of human hepatic stellate cells","volume":"118","author":"Bataller","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2019.06.004_bib70","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.peptides.2018.08.008","article-title":"Effects of angiotensin-(1-7) and angiotensin II on vascular tone in human cirrhotic splanchnic vessels","volume":"108","author":"Casey","year":"2018","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib71","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jhep.2010.03.013","article-title":"Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis","volume":"53","author":"Tandon","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2019.06.004_bib72","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3350\/cmh.2014.20.4.376","article-title":"Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension","volume":"20","author":"Kim","year":"2014","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2019.06.004_bib73","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s11845-018-1765-6","article-title":"Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials","volume":"187","author":"Yao","year":"2018","journal-title":"Ir J Med Sci"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib74","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","article-title":"Statins: old drugs as new therapy for liver diseases?","volume":"70","author":"Pose","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"27","key":"10.1016\/j.cld.2019.06.004_bib75","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.3748\/wjg.v22.i27.6201","article-title":"Pleiotropic effects of statins in the diseases of the liver","volume":"22","author":"Janicko","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cld.2019.06.004_bib76","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9","key":"10.1016\/j.cld.2019.06.004_bib77","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","article-title":"KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins","volume":"64","author":"Marrone","year":"2015","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib78","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase","volume":"46","author":"Trebicka","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2019.06.004_bib79","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2007.01.020","article-title":"Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats","volume":"46","author":"Abraldes","year":"2007","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2019.06.004_bib80","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1053\/j.gastro.2018.07.022","article-title":"Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension","volume":"155","author":"Tripathi","year":"2018","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.cld.2019.06.004_bib81","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial","volume":"47","author":"Pollo-Flores","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib82","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","article-title":"Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis","volume":"126","author":"Zafra","year":"2004","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib83","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study","volume":"30","author":"Bishnu","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2019.06.004_bib84","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/apt.14243","article-title":"Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study","volume":"46","author":"Bang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib85","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.29172","article-title":"Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study","volume":"66","author":"Chang","year":"2017","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2019.06.004_bib86","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1007\/s10620-014-3179-2","article-title":"Statin use in patients with cirrhosis: a retrospective cohort study","volume":"59","author":"Kumar","year":"2014","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib87","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis","volume":"150","author":"Mohanty","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2019.06.004_bib88","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib89","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/1744666X.2018.1440206","article-title":"Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations","volume":"14","author":"Selva-O'Callaghan","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib90","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Bjornsson","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib91","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4103\/0975-7406.171699","article-title":"Statins and its hepatic effects: newer data, implications, and changing recommendations","volume":"8","author":"Jose","year":"2016","journal-title":"J\u00a0Pharm Bioallied Sci"},{"issue":"10","key":"10.1016\/j.cld.2019.06.004_bib92","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1055\/s-0035-1564093","article-title":"The safety and benefit of statins in liver cirrhosis: a review","volume":"123","author":"Souk","year":"2015","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib93","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MAJ.0b013e3181e15da8","article-title":"Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians","volume":"340","author":"Rzouq","year":"2010","journal-title":"Am J Med Sci"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib94","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3350\/cmh.2016.0110","article-title":"Anticoagulation in cirrhosis: a new paradigm?","volume":"23","author":"Leonardi","year":"2017","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib95","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/j.gastro.2017.04.042","article-title":"Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis","volume":"153","author":"Loffredo","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib96","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cld.2016.08.009","article-title":"Drug hepatotoxicity: newer agents","volume":"21","author":"Bunchorntavakul","year":"2017","journal-title":"Clin Liver Dis"},{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib97","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0039-1679934","article-title":"Direct-acting oral anticoagulants in cirrhosis and cirrhosis-associated portal vein thrombosis","volume":"39","author":"Weinberg","year":"2019","journal-title":"Semin Liver Dis"},{"issue":"16","key":"10.1016\/j.cld.2019.06.004_bib98","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib99","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/14728214.2016.1184647","article-title":"Emerging therapies for portal hypertension in cirrhosis","volume":"21","author":"Nair","year":"2016","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.cld.2019.06.004_bib100","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818811294","article-title":"Advances in therapeutic options for portal hypertension","volume":"11","author":"Vilaseca","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2019.06.004_bib101","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/hep.22166","article-title":"Increased oxidative stress in cirrhotic rat livers: a potential mechanism contributing to reduced nitric oxide bioavailability","volume":"47","author":"Gracia-Sancho","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.06.004_bib102","doi-asserted-by":"crossref","first-page":"33453","DOI":"10.1038\/srep33453","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Sci Rep"},{"issue":"S1","key":"10.1016\/j.cld.2019.06.004_bib103","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0168-8278(14)60017-9","article-title":"Effect of the FXR Agonist Obeticholic acid on portal pressure in alcoholic cirrhosis: a proof of concept Phase 2a study","volume":"60","author":"Mookerjee","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2019.06.004_bib104","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/ajg.2015.185","article-title":"Effects of sapropterin on portal and systemic hemodynamics in patients with cirrhosis and portal hypertension: a bicentric double-blind placebo-controlled study","volume":"110","author":"Reverter","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2019.06.004_bib105","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.cgh.2010.01.017","article-title":"Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis","volume":"8","author":"Tandon","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib106","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.dld.2014.10.018","article-title":"The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study","volume":"47","author":"Kreisel","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib107","first-page":"e1002248","article-title":"Serelaxin as a potential treatment for renal dysfunction in cirrhosis: preclinical evaluation and results of a randomized phase 2 trial","volume":"14","author":"Snowdon","year":"2017"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib108","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3945\/ajcn.112.040469","article-title":"Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial","volume":"96","author":"De Gottardi","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib109","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/hep.21080","article-title":"Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension","volume":"43","author":"Hernandez-Guerra","year":"2006","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2019.06.004_bib110","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2010.07.034","article-title":"Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats","volume":"54","author":"Garcia-Caldero","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib111","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jhep.2012.09.010","article-title":"Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats","volume":"58","author":"Guillaume","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib112","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/gut.2008.149880","article-title":"Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension","volume":"58","author":"Lavina","year":"2009","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.cld.2019.06.004_bib113","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jhep.2012.12.012","article-title":"Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats","volume":"58","author":"Di Pascoli","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2019.06.004_bib114","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/hep.26520","article-title":"Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats","volume":"58","author":"Rosado","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib115","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hep.28686","article-title":"Inhibition of epoxyeicosatrienoic acid production in rats with cirrhosis has beneficial effects on portal hypertension by reducing splanchnic vasodilation","volume":"64","author":"Di Pascoli","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2019.06.004_bib116","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/hep.23596","article-title":"Treatment with the leukotriene inhibitor montelukast for 10\u00a0days attenuates portal hypertension in rat liver cirrhosis","volume":"51","author":"Steib","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2019.06.004_bib117","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/eci.12636","article-title":"Endothelin receptor blockers reduce shunting and angiogenesis in cirrhotic rats","volume":"46","author":"Hsu","year":"2016","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"10.1016\/j.cld.2019.06.004_bib118","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00228-011-1157-6","article-title":"Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis","volume":"68","author":"Lebrec","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.cld.2019.06.004_bib119","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/gut.2005.077453","article-title":"Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial","volume":"55","author":"Tripathi","year":"2006","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.cld.2019.06.004_bib120","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0168-8278(02)00295-7","article-title":"Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension","volume":"37","author":"Heller","year":"2002","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2019.06.004_bib121","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/hep.22170","article-title":"Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats","volume":"47","author":"Trebicka","year":"2008","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2019.06.004_bib122","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/hep.25845","article-title":"Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats","volume":"56","author":"Coll","year":"2012","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib123","doi-asserted-by":"crossref","first-page":"e16978","DOI":"10.1371\/journal.pone.0016978","article-title":"Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib","volume":"6","author":"Coriat","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib124","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2036.2011.04896.x","article-title":"The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study","volume":"35","author":"Pinter","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.cld.2019.06.004_bib125","doi-asserted-by":"crossref","first-page":"G1191","DOI":"10.1152\/ajpgi.00252.2011","article-title":"Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats","volume":"302","author":"D'Amico","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"6","key":"10.1016\/j.cld.2019.06.004_bib126","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1002\/hep.21921","article-title":"Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats","volume":"46","author":"Tugues","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2019.06.004_bib127","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/jgh.12480","article-title":"Beneficial effects of dual vascular endothelial growth factor receptor\/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats","volume":"29","author":"Lin","year":"2014","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2019.06.004_bib128","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/apt.14275","article-title":"Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy","volume":"46","author":"Kang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.cld.2019.06.004_bib129","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1365-2036.2009.03958.x","article-title":"Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis","volume":"29","author":"Vlachogiannakos","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib130","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/jgh.12070","article-title":"Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis","volume":"28","author":"Vlachogiannakos","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2019.06.004_bib131","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1053\/j.gastro.2014.08.031","article-title":"Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial","volume":"147","author":"Dhiman","year":"2014","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.cld.2019.06.004_bib132","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1111\/liv.12539","article-title":"Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites","volume":"34","author":"Rincon","year":"2014","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.cld.2019.06.004_bib133","doi-asserted-by":"crossref","first-page":"G301","DOI":"10.1152\/ajpgi.00010.2015","article-title":"Metformin reduces hepatic resistance and portal pressure in cirrhotic rats","volume":"309","author":"Tripathi","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib134","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1038\/s41598-017-02866-y","article-title":"Liraglutide improves liver microvascular dysfunction in cirrhosis: evidence from translational studies","volume":"7","author":"de Mesquita","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.cld.2019.06.004_bib135","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jhep.2011.12.008","article-title":"PPARalpha activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats","volume":"56","author":"Rodriguez-Vilarrupla","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2019.06.004_bib136","doi-asserted-by":"crossref","first-page":"G496","DOI":"10.1152\/ajpgi.00336.2012","article-title":"Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis","volume":"305","author":"Delgado","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"10.1016\/j.cld.2019.06.004_bib137","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/hep.30199","article-title":"Emricasan (IDN-6556) lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension","volume":"69","author":"Garcia-Tsao","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2019.06.004_bib138","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/liv.12570","article-title":"The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis","volume":"35","author":"Barreyro","year":"2015","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.cld.2019.06.004_bib139","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/apt.14377","article-title":"Randomised clinical study: the effects of oral taurine 6g\/day vs placebo on portal hypertension","volume":"47","author":"Schwarzer","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.cld.2019.06.004_bib140","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1002\/hep.27679","article-title":"Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rats","volume":"61","author":"Hsu","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2019.06.004_bib141","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20171015","article-title":"The beneficial effects of curcumin in cirrhotic rats with portal hypertension","volume":"37","author":"Hsu","year":"2017","journal-title":"Biosci Rep"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326119300431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326119300431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:57:28Z","timestamp":1761069448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326119300431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":141,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1089326119300431"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2019.06.004","relation":{},"ISSN":["1089-3261"],"issn-type":[{"type":"print","value":"1089-3261"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic Management of Portal Hypertension","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2019.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}